NewAmsterdam Pharma Company NAMS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's total equity?
- NewAmsterdam Pharma Company (NAMS) reported total equity of $665.22M in Q1 2026.
- How has NewAmsterdam Pharma Company's total equity changed year-over-year?
- NewAmsterdam Pharma Company's total equity decreased by 14.4% year-over-year, from $777.36M to $665.22M.
- What is the long-term trend for NewAmsterdam Pharma Company's total equity?
- Over 5 years (2020 to 2025), NewAmsterdam Pharma Company's total equity has grown at a 56.4% compound annual growth rate (CAGR), from -$73.04M to $683.43M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.